ALNYLAM PHARMACEUTICALS, INC


Jan 25, 05

08:04 ET Alnylam Initiates Program to Develop RNAi Therapeutics for Spinal Cord Injury

 
Jan 20, 05

08:02 ET Alnylam to Webcast Presentation at Piper Jaffray Health Care Conference on January 27, 2005

 
Jan 10, 05

08:01 ET Alnylam Scientists Report Progress on RSV Program and Systemic RNAi Therapeutics

 
Jan 06, 05

08:31 ET Alnylam to Webcast Presentation at 23rd Annual JPMorgan Healthcare Conference on January 12, 2005

 
08:03 ET Alnylam Pharmaceuticals Grants GeneCare Research Institute Licenses to Fundamental Intellectual Property for RNAi Therapeutics Directed Against Two Gene Targets

 
Jan 04, 05

08:04 ET Alnylam Pharmaceuticals Initiates RNAi Therapeutic Development Program for Respiratory Syncytial Virus Infection

 
Jan 03, 05

08:01 ET Alnylam Reports Progress in Strategic Alliance with Merck

 
Dec 08, 04

08:02 ET Alnylam Pharmaceuticals Presents Results Showing Potential of RNA Interference Therapeutics for Age-Related Macular Degeneration and Other Ocular Diseases

 
Nov 10, 04

16:01 ET Alnylam Pharmaceuticals Reports Third Quarter 2004 Financial Results

 
13:00 ET First In Vivo Demonstration of RNA Interference via Systemic Delivery is Published by Alnylam Scientists

 
Oct 27, 04

16:03 ET Alnylam Pharmaceuticals Presents Results Showing Reduction Of Alpha-Synuclein Expression By RNA Interference

 
Oct 25, 04

08:03 ET Alnylam to Webcast Conference Call Discussing Third Quarter 2004 Financial Results

 
Oct 19, 04

08:33 ET Alnylam and Isis Receive Exclusive License to Key microRNA Patents for Therapeutic Applications

 
Oct 18, 04

08:32 ET Alnylam to Webcast Presentation at Rodman & Renshaw Techvest 6th Annual Healthcare Conference on October 26, 2004

 
Sep 15, 04

08:30 ET Alnylam to Webcast Presentation at ThinkEquity Partners 2nd Annual Growth Conference on September 22, 2004

 
Sep 13, 04

08:07 ET Alnylam Pharmaceuticals Appoints Robert Millman as Chief Patent Counsel

 
Aug 04, 04

16:08 ET Alnylam Pharmaceuticals Reports Second Quarter 2004 Financial Results

 
Aug 03, 04

17:15 ET Alnylam to Webcast Presentation at the 24th Annual Adams, Harkness & Hill Summer Seminar on August 5, 2004

 
17:15 ET Hybridon Licenses Key VEGF Patents to Alnylam for Treatment of Ocular Diseases with RNAi Therapeutics

 
Jul 28, 04

09:01 ET Alnylam to Webcast Conference Call Discussing Second Quarter 2004 Financial Results

 
Jul 23, 04

09:02 ET Alnylam to Webcast Presentation at Banc Of America Securities 'New Products, New Paradigms In Health Care' Conference on July 29, 2004

 
Jul 19, 04

16:10 ET Alnylam Pharmaceuticals Announces Management Change

 
Jun 24, 04

09:01 ET Alnylam Pharmaceuticals Appoints Patricia Allen as Vice President of Finance

 
Jun 07, 04

08:33 ET Alnylam Pharmaceuticals Announces Exercise of Underwriters' Over-Allotment Option

 
May 27, 04

18:52 ET Alnylam Pharmaceuticals Announces Pricing of Initial Public Offering

 


Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.
Terms and conditions, including restrictions on redistribution, apply.
Copyright © 1996-2005 PR Newswire Association LLC. ALL Rights Reserved.
A United Business Media company.